Pulsenmore is an Israeli home-ultrasound maker that spent the first half of the year collecting the badges of a United States launch without collecting a United States P&L. Food and Drug Administration authorization arrived late in the prior year, Nasdaq trading opened in January, two clinic contracts were signed, the first patient scan was logged in February, and an e-commerce storefront went live in April. Those events change the addressable market on a slide. They do not yet change who pays the bills. Half-year product sales still sit on Clalit Health Services and a handful of Israeli hospital relationships, which is the same commercial spine the company had before the listing.
The operating engine is not the problem the market is pricing. Operating loss barely moved even as device shipments rose and a first slice of fertility-probe revenue was recognized. What blew out the bottom line was the June private placement: cash came in, but pre-funded and ordinary warrants were booked as liabilities whose day-one fair value exceeded the proceeds, turning a financing into the largest expense on the income statement. Liquid resources at mid-year still cover more than a year of the current operating cash use. That runway is real. It is also the only reason a sub-scale United States start can be attempted without an immediate second raise.
The half-year print therefore leaves a single unresolved question. Does the United States become a second revenue engine in the next two reporting periods, or does Clalit remain the entire franchise while warrant accounting and a thin public float keep rewriting the equity story? Conversion of early clinic logos, Ouma Health, and the newly registered United Kingdom fertility channel into invoiced sales is the test. Persistence of Israel-only mix is the falsifier.